ArticleHormones (Athens, Greece)2025
Modulation of adipose tissue phenotype and longevity-related gene expression by nuclear factor E2-related factor 2 knockdown in 3T3-L1 cells.
Article in Hormones (Athens, Greece), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study explores the role of nuclear factor E2-related factor 2 (Nrf2) in regulating adipose tissue phenotype and its potential mechanisms for promoting aging resistance in 3T3-L1 adipocytes. The study aims to evaluate the impact of Nrf2 knockdown on adipose phenotype transformation, focusing on brown adipose tissue (BAT) and white adipose tissue (WAT) marker genes, as well as longevity-related factors.
methods3T3-L1 preadipocytes were differentiated into adipocytes using a standard MDI regimen. Nrf2 expression was knocked down via siRNA transfection. Gene expression was assessed using quantitative real-time PCR (qPCR), and protein levels were analyzed using Western blotting.
resultsNrf2 knockdown was confirmed by Western blot (p<0.001) and qPCR (p<0.001), showing a significant reduction in Nrf2 expression. Notably, this knockdown resulted in increased expression of BAT markers, including PGC-1α (p = 0.012), Dio2 (p = 0.020), and PRDM16 (p = 0.001), at both mRNA (PGC-1α [p = 0.012], Dio2 [p = 0.020], and PRDM16 [p = 0.001]) and protein (PGC-1α [p = 0.001]; Dio2 [p = 0.003]; PRDM16 [p = 0.007])levels. Conversely, WAT markers such as BMP4 (mRNA: p = 0.01; WB: p = 0.001), resistin (mRNA: p = 0.016; WB: p = 0.004), and Rb1 (mRNA: p = 0.03; WB: p = 0.003) were significantly downregulated. Additionally, levels of Cycs (mRNA: p = 0.024; WB: p = 0.037) and UCP1 (mRNA: p = 0.024; WB: p = 0.023) were elevated, indicating enhanced mitochondrial function and metabolic activity (P < 0.05). The knockdown also affected longevity-related proteins, Sirt1 (WB: p = 0.018) and AMPKα (WB: p = 0.021), underscoring Nrf2's role in metabolic regulation.
conclusionNrf2 knockdown in 3T3-L1 adipocytes promotes a transition towards a brown adipose phenotype and enhances the expression of longevity-related factors, suggesting Nrf2 as a potential therapeutic target for addressing aging-related metabolic decline.
Indexed as
Identifiers
40341662What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.